Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MDIG
is known to be overexpressed in many types of human cancers and has demonstrated predictive power in the prognosis of cancer, although the functions and mechanisms of
MDIG
in liver cancer, especially in hepatocellular carcinoma (HCC), are still unknown. In this study, we report that
MDIG
and MYC were negatively regulated by IKZF1.
MDIG
overexpression substantially promoted HCC cell proliferation, cell migration and spreading, whereas knockdown of
MDIG
would reverse above-mentioned effect.
MDIG
effects on tumour cell growth were further demonstrated in a tumour xenograft model. Moreover,
MDIG
had effects on the level of p21(CIP1/WAF1) via H3K9me3 expression in HCC.
MDIG
was also found to be closely related to the sorafenib resistance of HCC cells in vitro. Clinically, we found that
MDIG
was frequently overexpressed in human HCCs (69.7%; n=155) and was significantly associated with histological grade and
hepatitis B
virus infection. Our findings indicate that
MDIG
plays an important role in HCC progression via
MDIG
/H3K9me3/p21(CIP1/WAF1) signalling and serves as a potential therapeutic target.
...
PMID:Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. 2847 46